Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Cancers, Free Full-Text

Nivolumab and Relatlimab for Advanced Melanoma - NCI

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma

Cancers, Free Full-Text

Cancers, Free Full-Text

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma

Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?

PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma